# A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

> **NCT04029909** · PHASE1 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 12 (estimated)

## Conditions studied

- Ovarian Epithelial Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Gimatecan 0.6mg/m2/d
- **DRUG:** 0.8mg/m2/d
- **DRUG:** 0.4mg/m2/d

## Key facts

- **NCT ID:** NCT04029909
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-11
- **Primary completion:** 2019-12
- **Final completion:** 2022-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029909, "A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04029909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*